Prophylactic Use of Cranberry Extract May Help Decrease the Incidence of Urinary Tract Infections, Urinary Symptoms, and Antibiotic Use in Prostate Cancer Patients on Radiotherapy.
Prophylactic use of the cranberry extract in patients diagnosed with prostatic adenocarcinoma and treated with radiotherapy resulted in decreased incidence of lower urinary tract infections (LUTIs) and decreased antibiotic use.
In this randomized, open-label, controlled study, patients received either enteric-coated tablets containing cranberry extract (200 mg/day) (n=924; mean age: ~70 years) or placebo (n=435) for 6–7 weeks.
At the end of the study group taking cranberry extract tablets had lower incidence of LUTIs compared to control (i.e. 10.8% vs. 24.6%; P = 0.0001), which in turn resulted in less antibiotic use (total: 285 days vs. 585 days, respectively; P = 0.001). Additionally, incidence of dysuria (i.e. painful urination) was significantly lower in cranberry group with the control group (i.e. 62.8% vs. 36.6%, respectively; P = 0.001). Use of non-steroidal anti-inflammatory drugs (NSAIDs) by patients to treat urinary symptoms was reduced by half in cranberry group when compared to control (i.e. 23.1% vs. 46.2%, respectively; P = 0.001). Similar findings were reported about other urinary symptoms as well, wherein cranberry group showed better relief.
Overall, it was concluded that prophylactic use of cranberry extract was correlated with a lower risk of developing a LUTIs and reduced urinary discomfort, and helped in reducing need of antibiotic treatment by about half. This benefit would be beneficial in reducing generation of bacterial resistance to antibiotics.
Reference:- Res Rep Urol. 2017;9:65–9.